Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells.

ABSTRACT: Acute myeloid leukemia (AML) is an hematologic neoplasia characterized by the accumulation of transformed immature myeloid cells in bone marrow. Although the response rate to induction therapy is high, survival rate 5-year after diagnosis is still low, highlighting the necessity of new novel agents. To identify agents with the capability to abolish the self-renewal capacity of AML blasts, an in silico screening was performed to search for small molecules that induce terminal differentiation. Emetine, a hit compound, was validated for its anti-leukemic effect in vitro, ex vivo and in vivo. Emetine, a second-line anti-protozoa drug, differentially reduced cell viability and clonogenic capacity of AML primary patient samples, sparing healthy blood cells. Emetine treatment markedly reduced AML

SUBMITTER: Cornet-Masana JM 

PROVIDER: S-EPMC5029623 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature